CSIMarket Company Name, Ticker, Industry, else..
 
Beam Therapeutics Inc   (NASDAQ: BEAM)
 
Price: $29.6600 $0.20 0.679%
Day's High: $29.969999313354492 Week Perf: 0.78 %
Day's Low: $ 28.91 30 Day Perf: 8.84 %
Volume (M): 1,133,686 52 Wk High: $ 38.26
Volume (M$): $ 0 52 Wk Avg: $27.67
Open: $28.91 52 Wk Low: $19.35



 Market Capitalization (Millions $) 3,094
 Shares Outstanding (Millions) 104
 Employees 511
 Revenues (TTM) (Millions $) 156
 Net Income (TTM) (Millions $) -85
 Cash Flow (TTM) (Millions $) 6
 Capital Exp. (TTM) (Millions $) 13

Business Description




   Company Address: 238 Main Street Cambridge 2142 MA
   Company Phone Number: 327-8775   Stock Exchange / Ticker: NASDAQ BEAM


Customers Net Income grew by BEAM's Customers Net Profit Margin grew to

43.16 %
10.28 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ATRA        6.09% 
AUTL   -4.27%    
LENZ        16.63% 
MGTX        0.51% 
PLX        5.12% 
RGNX   -7.45%    
• View Complete Report
   



Product Service News

Beam Therapeutics Reports Promising Data for BEAM-302 in AATD Amidst Financial Challenges

Published Sat, Apr 5 2025 11:20 PM UTC

Beam Therapeutics, a prominent player in the gene-editing sector, has released promising new data on its investigational therapy, BEAM-302, for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) at the 7th Global Research Conference and 10th Patient Congress organized by the Alpha-1 Foundation. The company reported that in the 60 mg cohort (n=3), the treatment led to a...
Clinical Study

Promising Advances in Sickle Cell Disease Treatment Beam Therapeutics Unveils BEAM-101 Trial Data Amidst Financial Ch...

Published Sat, Dec 7 2024 4:30 PM UTC

Beam Therapeutics Inc. has made significant strides in the treatment of sickle cell disease, presenting groundbreaking new data from its BEACON Phase 1/2 clinical trial of BEAM-101 during the recent American Society of Hematology (ASH) Annual Meeting. Notably, all seven patients who received BEAM-101 displayed remarkable results: a hemoglobin F (HbF) induction exceeding 60%,...
Clinical Study

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle C...

Published Tue, Nov 5 2024 2:00 PM UTC

Advancements in Hematology: Beam Therapeutics Innovative Research Amidst Financial Challenges Beam Therapeutics, a leading biotechnology company focused on developing precision genetic medicines through base editing, recently made significant presentations at the American Society of Hematology (ASH) Annual Meeting. The data presented encapsulates crucial insights from thei...
Clinical Study

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency ...

Published Wed, Jun 26 2024 10:30 AM UTC

Beam Therapeutics Groundbreaking BEAM-302 Enters Clinical Trial for Alpha-1 Antitrypsin Deficiency, While Suppliers Face Financial ChallengesConclusion:Beam Therapeutics Inc. s dosing of the first patient with BEAM-302 in the Phase 1/2 clinical trial for severe alpha-1 antitrypsin deficiency represents a significant advancement in precision genetic medicines. The therapy s ...
Clinical Study

Beam Therapeutics Optimized Manufacturing Process Boosts Sickle Cell Disease Therapy Development

Published Fri, Jun 14 2024 7:00 AM UTC

Beam Therapeutics, a leading biotechnology company specializing in precision genetic medicines through base editing, has announced significant progress in the manufacturing process for BEAM-101, an investigational base editing therapeutic for sickle cell disease (SCD). The company presented data at the European Hematology Association (EHA) Hybrid Congress, highlighting the s...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 19.83
Price to Sales (Expected) -
Price to Book 2.9
PEG (TTM) -

Financial Strength Current
Quick Ratio 26.37
Working Capital Ratio 26.69
Leverage Ratio (MRQ) 0.3
Total Debt to Equity 0.09
Interest Coverage (TTM) -
Debt Coverage (TTM) 1.19

Per Share Current
Earnings (TTM) -0.73 $
Revenues (TTM) 1.5 $
Cash Flow (TTM) 0.06 $
Cash 20.45 $
Book Value 10.23 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 305,352
Net Income per Employee (TTM) -167,176
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.09

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -25827.14 %
Net Margin (MRQ) -25036.33 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Beam Therapeutics Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.